Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
I
Iadecola, Sara
Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori
(
P 179
)
IMMUNOSUPPRESSIVE MYELOID CELLS ARE INCREASED IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND ARE NEGATIVELY ASSOCIATED WITH SURVIVAL
Sara Iadecola
Favorite
Ibrahim, Toni
Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
(
P 031
)
PAZOPANIB IN ADVANCED BONE SARCOMA: A RETROSPECTIVE ANALYSIS OF RIZZOLI ORTHOPEDIC INSTITUTE
Toni Ibrahim
Favorite
(
P 148
)
ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Toni Ibrahim
Favorite
(
P 195
)
THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Toni Ibrahim
Favorite
(
P 245
)
MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Toni Ibrahim
Favorite
(
P 250
)
SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Toni Ibrahim
Favorite
Iida, Keiichiro
Kyushu University Department of Orthopaedic Surgery
(
P 125
)
EFFECTIVENESS OF PERIPHERAL BLOOD IMMUNE-RELATED MARKERS IN SELECTING NOVEL THERAPEUTIC AGENTS FOR ADVANCED SOFT TISSUE SARCOMA
Keiichiro Iida
Favorite
IJzerman, Nikki
Netherlands Cancer Institute and Erasmus MC Cancer Institute
(
P 103
)
GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY
Nikki IJzerman
Favorite
Ikuta, Kunihiro
Nagoya University Hospital
(
P 262
)
CLINICAL RESULTS OF ACTIVE SURVEILLANCE FOR EXTRA ABDOMINAL DESMOID TYPE FIBROMATOSIS
Kunihiro Ikuta
Favorite
(
P 322
)
PHASE 2 SINGLE-ARM CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AURANOFIN IN ADULT PATIENTS WITH PROGRESSIVE DESMOID
Kunihiro Ikuta
Favorite
Imagama, Shiro
Nagoya University Hospital
(
P 262
)
CLINICAL RESULTS OF ACTIVE SURVEILLANCE FOR EXTRA ABDOMINAL DESMOID TYPE FIBROMATOSIS
Shiro Imagama
Favorite
(
P 322
)
PHASE 2 SINGLE-ARM CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AURANOFIN IN ADULT PATIENTS WITH PROGRESSIVE DESMOID
Shiro Imagama
Favorite
Imai, Toru
Department of Medical Oncology, National Cancer Center Hospital
(
P 147
)
ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Toru Imai
Favorite
(
P 150
)
CLINICAL CHARACTERISTICS OF PRIMARY CUTANEOUS AND SUBCUTANEOUS EWING SARCOMA FAMILY OF TUMORS
Toru Imai
Favorite
Imene, Deneche
Gustave Roussy
(
P 060
)
TOWARD A NEW GENOMIC AND CLINICO-PATHOLOGIC CLASSIFICATION OF UTERINE ADENOSARCOMAS
Deneche Imene
Favorite
Indelicato, Daniel
University of Florida
(
P 023
)
FACTORS ASSOCIATED WITH LOCAL CONTROL AND SURVIVAL IN LOCALIZED EWING SARCOMA PATIENTS TREATED WITH SURGERY ON AEWS1031: A REPORT FROM THE CHILDRENS ONCOLOGY GROUP
Daniel Indelicato
Favorite
Ingalls, Kimberly
Zentalis
(
P 144
)
A PHASE 1/2 DOSE ESCALATION/EXPANSION STUDY OF ZN-C3 PLUS GEMCITABINE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Kimberly Ingalls
Favorite
Inigo, Fatima
Research Institute of the McGill University Health Centre
(
P 030
)
OSTEOSARCOMA PATIENT-DERIVED-XENOGRAFTS A RELEVANT MODEL TO STUDY CHEMOTHERAPEUTIC AND METASTATIC EVENTS
Fatima Inigo
Favorite
Innis, Scott
Foghorn Therapeutics
(
P 187
)
PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA
Scott Innis
Favorite
Ip-Toma, Christina
MIB Agents
(
P 310
)
TUMOR REVIEW BOARD FOR OSTEOSARCOMA (TURBO): BIMONTHLY, MULTI-INSTITUTIONAL, MULTIDISCIPLINARY VIRTUAL TUMOR BOARD FOR OSTEOSARCOMA
Christina Ip-Toma
Favorite
Irish, Jonathan
Division of Head and Neck Surgery, Princess Margaret Hospital, University of Toronto, Ontario, Canada
(
P 290
)
OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
Jonathan Irish
Favorite
Isakoff, Michael
University of Connecticut
(
P 237
)
EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Michael Isakoff
Favorite
Isern, Josep
Hospital de la Santa Creu i Sant Pau
(
P 225
)
TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Josep Isern
Favorite
Ishii, Takeaki
Research Institute of the McGill University Health Centre
(
P 030
)
OSTEOSARCOMA PATIENT-DERIVED-XENOGRAFTS A RELEVANT MODEL TO STUDY CHEMOTHERAPEUTIC AND METASTATIC EVENTS
Takeaki Ishii
Favorite
Isler, Marc
University of Montreal
(
P 054
)
PROGNOSTIC FACTORS AFFECTING SURVIVAL OF PATIENTS WITH PRIMARY MUSCULOSKELETAL SARCOMAS FOLLOWING PULMONARY METASTASECTOMY
Marc Isler
Favorite
(
P 308
)
REFERRAL DELAYS OF QUEBEC SARCOMA POPULATION : A PROSPECTIVE COHORT STUDY
Marc Isler
Favorite
Ito, Kan
Nagoya University Hospital
(
P 262
)
CLINICAL RESULTS OF ACTIVE SURVEILLANCE FOR EXTRA ABDOMINAL DESMOID TYPE FIBROMATOSIS
Kan Ito
Favorite
(
P 322
)
PHASE 2 SINGLE-ARM CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AURANOFIN IN ADULT PATIENTS WITH PROGRESSIVE DESMOID
Kan Ito
Favorite
Itri, Loretta
litri@aadibio.com
(
P 167
)
STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Loretta Itri
Favorite
(
P 313
)
A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Loretta Itri
Favorite
Iturregui, Jose
Mayo Clinic
(
P 064
)
A SYSTEMATIC REVIEW OF PATIENT-REPORTED OUTCOMES USED TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN SOFT-TISSUE SARCOMA
Jose Iturregui
Favorite
(
P 082
)
PATIENT-REPORTED OUTCOME MEASURES TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN PEOPLE WITH SOFT-TISSUE SARCOMA: A SYSTEMATIC REVIEW OF MEASUREMENT PROPERTIES OF PATIENT-REPORTED OUTCOMES
Jose Iturregui
Favorite
(
P 092
)
THE SARCOMA-SPECIFIC QUALITY OF LIFE STUDY (SARC-QOL): IDENTIFYING KEY DOMAINS OF HEALTH-RELATED QUALITY OF LIFE IN ADULT PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA
Jose Iturregui
Favorite
Iuliani, Michele
Campus Bio-Medico University of Rome
(
P 185
)
PHARMACOLOGICAL INHIBITION OF GLYOXALASE-1 AS NOVEL THERAPEUTIC STRATEGY TO POTENTIATE TRABECTEDIN ANTI-TUMOR EFFECT IN SOFT TISSUE SARCOMA PRECLINICAL MODELS
Michele Iuliani
Favorite
Iwaniak, Krzysztof
Medical University of Warsaw
(
P 169
)
WHAT IS THE MOSTAPPROPRIATE STUDY ENDPOINT FOR PHASE IICLINICAL TRIALS IN SOFT TISSUE SARCOMA? - CHARACTERISTIC OF THE CURRENT LANDSCAPE OF PHASE II TRIALS
Krzysztof Iwaniak
Favorite
Iwata, Shintaro
National Cancer Center Hospital
(
P 069
)
CLINICOPATHOLOGICAL FEATURES AND TREATMENT PATHWAYS OF SOFT TISSUE SARCOMA BY TISSUE OF ORIGIN
Shintaro Iwata
Favorite
(
P 147
)
ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Shintaro Iwata
Favorite
(
P 150
)
CLINICAL CHARACTERISTICS OF PRIMARY CUTANEOUS AND SUBCUTANEOUS EWING SARCOMA FAMILY OF TUMORS
Shintaro Iwata
Favorite
(
P 218
)
PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Shintaro Iwata
Favorite
Iwatsu, Jun
Tohoku University Graduated school of Medicine
(
P 091
)
THE PROGNOSIS OF PULMONARY METASTASIS AFTER THE SURGERY FOR PRIMARY LESION IN ELDERLY HIGH-GRADE SARCOMA PATIENTS
Jun Iwatsu
Favorite
iwatsu, jun
Tohoku University Graduate School of Medicine
(
P 209
)
THE OUTCOME OF R1 EXCISION COMBINED WITH ADJUVANT RADIOTHERAPY FOR SOFT TISSUE SARCOMA IN ELDERLY PATIENTS
jun iwatsu
Favorite
Iyer, Gopa
Memorial Sloan Kettering Cancer Center
(
P 313
)
A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Gopa Iyer
Favorite
Back to Top
